Future Directions in the Treatment of Osteosarcoma

Osteosarcoma is the most common primary bone sarcoma and is often diagnosed in the 2nd–3rd decades of life. Response to the aggressive and highly toxic neoadjuvant methotrexate-doxorubicin-cisplatin (MAP) chemotherapy schedule is strongly predictive of outcome. Outcomes for patients with osteosarcom...

Descripción completa

Detalles Bibliográficos
Autores principales: Smrke, Alannah, Anderson, Peter M., Gulia, Ashish, Gennatas, Spyridon, Huang, Paul H., Jones, Robin L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7829872/
https://www.ncbi.nlm.nih.gov/pubmed/33467756
http://dx.doi.org/10.3390/cells10010172

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7829872/
https://www.ncbi.nlm.nih.gov/pubmed/33467756
http://dx.doi.org/10.3390/cells10010172

Ejemplares similares